The Efficacy and Mechanism of Acupuncture Treatment in Patients With Subjective Cognitive Decline

Sponsor
Beijing Hospital of Traditional Chinese Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT03444896
Collaborator
(none)
60
1
2
22.2
2.7

Study Details

Study Description

Brief Summary

This study evaluates the efficacy and mechanism of acupuncture treatment in patients with subjective cognitive decline. Half of patients will receive acupuncture treatment for 12 weeks, while the other half will receive sham acupuncture treatment for 12 weeks .

Condition or Disease Intervention/Treatment Phase
  • Device: Acupuncture group
  • Device: Sham acupuncture group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Efficacy and Neural Mechanism of Acupuncture Treatment in Older Adults With Subjective Cognitive Decline: a Randomized Controlled Trial
Actual Study Start Date :
Apr 25, 2018
Anticipated Primary Completion Date :
Jan 1, 2020
Anticipated Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acupuncture group

Device: Acupuncture group
Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.

Placebo Comparator: Sham acupuncture group

Device: Sham acupuncture group
Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.

Outcome Measures

Primary Outcome Measures

  1. Change in cognitive function [Changes from baseline at 12 weeks]

    A composite score will be computed by averaging z-scores from Animal Fluency Test, Digit Symbol Substitution Test, Trail-Making Test Parts A and B, Stroop Color Word Test C, Digit Span Test, Boston Naming Test, Clock Drawing Test and Auditory Verbal Learning Test delayed recall and delayed recognition.

Secondary Outcome Measures

  1. Neuroplasticity outcome [baseline and 12 weeks]

    Neuroplasticity outcome changes are measured by structural MRI (including DTI), task functional MRI, resting state functional MRI and arterial spin labeling.

Other Outcome Measures

  1. The degree of complaint in cognitive decline [baseline and 12 weeks]

    measured by Subjective Cognitive Decline Questionnaire.

  2. The sleep quality [baseline and 12 weeks]

    Measured by Pittsburgh Sleep Quality Index

  3. The depressive symptoms [baseline and 12 weeks]

    Measured by Geriatric depression scale

  4. The face recognition ability and sense of direction [baseline and 12 weeks]

    Measured by Face recognition questionnaire and Santa Barbara Sense of Direction scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Male and female adults aged 55-75;

  2. Native Chinese speakers with right-handed and at least a primary school education;

  3. Self-reported persistent memory decline, which was confirmed by caregivers;

  4. Normal general cognitive function and not meeting the criterion of mild cognitive impairment, as defined by performance within the normal range on both measures within at least one cognitive domain or in each of the three cognitive domains sampled (adjusted for age and education);

  5. No or minimal impairment in activities of daily living;

Exclusion Criteria:
  1. Presence of positive neurologic history (e.g., traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, etc.) ;

  2. treatments that would affect cognitive function;

  3. Presence of significant psychiatric history (e.g., bipolar disorder, schizophrenia, etc.) and/or severe anxiety and depression;

  4. Presence of serious heart, kidney, liver, gastrointestinal, infectious, endocrine disease or cancer;

  5. History of alcohol or drug abuse/addiction in nearly two years;

  6. Any contraindications for magnetic resonance imaging (MRI) scans (e.g., aneurysm clip pacemaker, etc.);

  7. Significant visual and/or auditory impairment uncorrected by aids, and unable to perform neuropsychological evaluations;

  8. Currently enrolled in another research study;

  9. Received acupuncture treatment in the preceding month.

Contacts and Locations

Locations

Site City State Country Postal Code
1 School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine Beijing Beijing China 100029

Sponsors and Collaborators

  • Beijing Hospital of Traditional Chinese Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ping Zhou, doctor, Beijing Hospital of Traditional Chinese Medicine
ClinicalTrials.gov Identifier:
NCT03444896
Other Study ID Numbers:
  • 2017BL-061-03
First Posted:
Feb 26, 2018
Last Update Posted:
Jun 17, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 17, 2019